<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="42007">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02096224</url>
  </required_header>
  <id_info>
    <org_study_id>CRBDSevoDes</org_study_id>
    <nct_id>NCT02096224</nct_id>
  </id_info>
  <brief_title>Sevoflurane Versus Desflurane for Catheter-related Bladder Discomfort</brief_title>
  <official_title>Comparison of the Effects of Sevoflurane and Desflurane on Prevention of Catheter-related Bladder Discomfort</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <authority>Korea: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We want to evaluate the efficacy of the sevoflurane and desflurane for the prevention of
      catheter-related bladder discomfort.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The mechanism of catheter-related bladder discomfort is thought to be related to the
      muscarinic receptor. The volatile anesthetics such as sevoflurane and desflurane are known
      to block the muscarinic receptor in different ways.

      We want to evaluate the efficacy of the sevoflurane and desflurane for the prevention of
      catheter-related bladder discomfort.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Catheter-related bladder discomfort</measure>
    <time_frame>1 hour postoperatively</time_frame>
    <safety_issue>No</safety_issue>
    <description>Catheter-related bladder discomfort will be measured at 1 hour postoperatively (0:none, 1:mild, 2:moderate, 3:severe).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Catheter-related bladder discomfort</measure>
    <time_frame>0, 6 and 24 hour postoperatively</time_frame>
    <safety_issue>No</safety_issue>
    <description>Catheter-related bladder discomfort will be measured at 1 hour postoperatively (0:none, 1:mild, 2:moderate, 3:severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nausea</measure>
    <time_frame>0, 1, 6 and 24 hour postoperatively</time_frame>
    <safety_issue>No</safety_issue>
    <description>The degree of nausea will be assessed as none, mild, moderate and severe at 0, 1, 6 and 24 hour postoperatively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vomiting</measure>
    <time_frame>0, 1, 6 and 24 hour postoperatively</time_frame>
    <safety_issue>No</safety_issue>
    <description>The degree of vomiting will be assessed as none, mild, moderate and severe at 0, 1, 6 and 24 hour postoperatively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety</measure>
    <time_frame>0 houe after admission of operating room</time_frame>
    <safety_issue>No</safety_issue>
    <description>Anxiety score after the admission of operating room will be assessed. (score:0-10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Agitation</measure>
    <time_frame>0 hour after admision of post-anesthesia care unit</time_frame>
    <safety_issue>No</safety_issue>
    <description>Agitation will be assessed using Riker sedation-agitated scale at 0 hour after admission of post-anesthesia care unit.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">92</enrollment>
  <condition>Catheter Site Discomfort</condition>
  <condition>Complications</condition>
  <condition>Anesthesia</condition>
  <condition>Urinary Bladder Neoplasms</condition>
  <arm_group>
    <arm_group_label>Sevoflurane</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sevoflurane will be administered as the maintenance agent of general anesthesia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Desflurane</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Desflurane will be administered as the maintenance agent of general anesthesia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevoflurane</intervention_name>
    <description>Sevoflurane will be used.</description>
    <arm_group_label>Sevoflurane</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desflurane</intervention_name>
    <description>Desflurane will be used</description>
    <arm_group_label>Desflurane</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients scheduled for transurethral bladder excision under general anesthesia

          -  ASA I-III

        Exclusion Criteria:

          -  Foley catheter less than 18 Fr.

          -  Patients with obstruction of urinary tract

          -  Patients with neurogenic bladder

          -  Patients with severe obesity

          -  Patients with neurologic disorder

          -  Patients with chronic pain
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hee-Pyoung Park, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Seoul National University of Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hyun-Chang Kim, MD</last_name>
    <phone>+821028862876</phone>
    <email>onidori1979@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University of Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hee-Pyoung Park, PhD</last_name>
      <phone>+821029717647</phone>
      <email>hppark@snu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Hyun-Chang Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hee-Pyoung Park, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 21, 2014</lastchanged_date>
  <firstreceived_date>March 21, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Desflurane</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
